The introduction of Retatrutide in the United Kingdom is creating significant anticipation within the weight management community. This groundbreaking dual agonist – targeting both GLP-1 and GIP – promises a potentially new approach to combating excess weight . Until recently, options have been restricted for many, and Retatrutide represents a